Sphingosine kinase-1 protects multiple myeloma from apoptosis driven by cancer specific inhibition of RTKs

Shuntaro Tsukamoto†, Yuhui Huang†, Motofumi Kumazoe, Connie Lesnick, Shuhei Yamada, Naoki Ueda, Takashi Suzuki, Shuya Yamashita, Yoon Hee Kim, Yoshinori Fujimura, Daisuke Miura, Neil E Kay, Tait D Shanafelt and Hirofumi Tachibana

1 Division of Applied Biological Chemistry, Department of Bioscience and Biotechnology, Faculty of Agriculture, Kyushu University, Fukuoka 812-8581, Japan
2 Food Functional Design Research Center, Kyushu University, Fukuoka 812-8581, Japan
3 Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA
4 Innovation Center for Medical Redox Navigation, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan

* Corresponding author: Hirofumi Tachibana, 6-10-1 Hakozaki, Higashi-ku, Fukuoka 812-8581, Japan. Tel and Fax: (+81) (92) 642-3008 E-mail: tatibana@agr.kyushu-u.ac.jp

† Both authors contributed equally to this work.

Financial support: This work was kindly supported in part by Grants-in-Aid for Scientific Research (KAKENHI) from the Japan Society for the Promotion of Science to H. Tachibana (Grant Number 22228002 and 15H02448); International Myeloma Foundation (IMF) Japan's grants to H. Tachibana; Research Fellowship for Young Scientists from the Japan Society for the Promotion of Science DC2 (11J01340) to S. Tsukamoto and DC1 (13J03437) to Y. Huang; and MEXT Funding-Project for Developing Innovation Systems-Creation of Innovation.
Centers for Advanced Interdisciplinary Research Areas Program in Japan to Y. Fujimura and D. Miura.

**Keywords:** SphK1, ASM, RTK, cancer specific cell death, 67LR

**Word count:** 3,405

**Total number of figures:** 6

**Conflict of interest:** T. Shanafelt reports research support from Polyphenon E International. The remaining authors declare no competing financial interests.

**Running title:** Cancer-specific apoptosis by targeting 67LR and SphK1
Abstract

Activation of acid sphingomyelinase (ASM) leads to ceramide accumulation and induces apoptotic cell death in cancer cells. In the present study, we demonstrate that the activation of ASM by targeting cancer-overexpressed 67-kDa laminin receptors (67LR) induces lipid raft disruption and inhibits receptor tyrosine kinase (RTK) activation in multiple myeloma (MM) cells. Sphingosine kinase 1 (SphK1), a negative regulator of ceramide accumulation with anti-apoptotic effects, was markedly elevated in MM cells. The silencing of SphK1 potentiated the apoptotic effects of the green tea polyphenol epigallocatechin-3-O-gallate (EGCG), an activator of ASM through 67LR. Further, the SphK1 inhibitor safinogol synergistically sensitized EGCG-induced pro-apoptotic cell death and tumor suppression in MM cells, by promoting the prevention of RTK phosphorylation and activation of death-associated protein kinase 1 (DAPK1). We propose that targeting 67LR/ASM and SphK1 may represent a novel therapeutic strategy against MM.
Introduction

Multiple myeloma (MM) is the second most common hematologic malignancy. It is an incurable disease with an average survival of 5 years following high-dose chemotherapy and autologous stem cell transplantation or treatment with novel drugs such as lenalidomide and bortezomib (1). The 67-kDa laminin receptor (67LR) is over-expressed in various cancers including MM (2), acute myeloid leukemia (AML) (3), colorectal carcinoma (4), and breast carcinoma (5). Pathological studies suggest that increased 67LR expression is correlated with lesions histological severity and tumor progression (4). Furthermore, 67LR over-expression in cancer has also been linked with increased expression levels of cyclins A and B and cyclin-dependent kinases (CDK)-1 and -2, while a mouse 67LR-knockdown model exhibited markedly reduced tumor growth (6). In addition, the over-expression of 67LR can also induce adhesion-mediated drug resistance and chemotherapy resistance (7). Therefore, these findings support a vital role for 67LR in cancer progression.

The green tea polyphenol epigallocatechin-3-O-gallate (EGCG) inhibits tumor cell growth and induces apoptosis in cancer cells without adversely affecting normal cells (2,3,8). Several clinical trials have been conducted to evaluate its potential role in cancer treatment (9-11). 67LR has been identified as a cell-surface EGCG receptor that mediates an anti-tumor effect of EGCG in vivo (12,13). Furthermore, 67LR is required for EGCG-induced selective killing of MM and AML cells, whereas peripheral blood mononuclear cells (PBMCs) are spared (2,3). Such findings provide a rationale for the clinical evaluation of EGCG as a 67LR-targeting drug. However, the concentrations of EGCG required to achieve sufficient killing of MM cells are much higher than the plasma concentrations achieved in clinical trials till date. Therefore, we focused on the key mediator of 67LR-dependent apoptotic cell death and amplified it using a molecular targeting strategy.
Insulin-like growth factor 1 receptor (IGF-1R) regulates the proliferation, survival, and metastasis of many cancer cells, including MM cells. Recent studies have shown that targeting IGF-1R has impressive anti-cancer activity in both in vitro and in vivo models of breast, prostate, and colon cancers (14). EGCG has been proven as a potent inhibitor of IGF-1R in colon cancer cells (15). However, the influence of EGCG on IGF-1R activity in MM cells remains unknown.

Acid sphingomyelinase (ASM) acts on membrane sphingomyelin to generate ceramide, which mediates cell death induced by diverse stimuli, such as ionizing radiation, chemotherapeutic agents and ultraviolet A (UVA) light (16). Additionally, ASM-induced generation of ceramide leads to displacement of cholesterol from lipid rafts on the plasma membrane (17). However, whether ASM influences cholesterol-rich lipid raft formation, which is associated with receptor tyrosine kinase (RTK) activation (18), is unknown. We have previously reported the mechanisms by which protein kinase C (PKC) delta and ASM mediate EGCG-induced cell death via 67LR (19). However, whether 67LR/ASM signaling is involved in the inhibition of RTK activity remains unclear.

Sphingosine kinase 1 (SphK1) is over-expressed in multiple cancers including those of the breast, prostate, ovary and lung (20). SphK1 catalyzes the phosphorylation of sphingosine, promoting ceramide metabolism and formation of sphingosine-1-phosphate (S1P) (21). S1P then activates G protein-coupled receptors that control multiple cellular processes including anti-apoptosis, cell proliferation and angiogenesis (21). Therefore, SphK1 regulates a rheostat, balancing the effects of pro-apoptotic ceramide and pro-proliferative S1P; and inhibiting SphK1 and down-regulating S1P is a rational therapeutic target for cancer therapy (22). L-threo-dihydrosphingosine (safingol) is a competitive inhibitor of SphK1, which first entered clinical trials as an anti-cancer agent. Unfortunately, safingol has limited single-agent activity
in vivo, and strategies to increase its effectiveness in cancer treatment without increasing toxicity are urgently required (23).

We demonstrate that over-expression of SphK1 attenuates 67LR-dependent cancer cell death induced by EGCG. Our findings demonstrate that a novel combination of therapeutic agents (EGCG and safingol) shows potent synergistic toxicity in MM cells, without affecting normal cells. The stimulation of ceramide generation by targeting 67LR and SphK1 is a simple and efficient strategy for myeloma-specific chemotherapy.
Materials and Methods

Materials and antibodies

EGCG, BODIPY-C12-Sphingomyelin, catalase and propidium iodide (PI) were purchased from Sigma (St. Louis, MO). Annexin V-Alexa fluor 488 and DiIC16 were obtained from Life Technologies Corporation (Carlsbad, CA). Safingol was purchased from Avanti Polar Lipids, Inc. (Alabaster, AL, USA). Anti-ASM (H-181) and anti-phospho-EGFR (Y1173) antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA); anti-67LR (MLuC5) and anti-SphK1 antibodies were purchased from Abcam (Tokyo, Japan). Anti-phospho-IGF-1R (Y1131), anti-IGF-1R, anti-EGFR and anti-DAPK1 antibodies were purchased from Cell Signaling Technology (Danvers, MA). Anti-67LR serum was obtained from a rabbit, which had been immunized with synthesized peptides corresponding to residues 161–170 of human 67LR (24). Acid sphingomyelinase activity assay kit was obtained from Echelon biosciences (UT, USA).

Patient samples and cell culture

Primary MM cells were isolated from bone marrow aspirate samples obtained from MM patients. Patients provided informed consent and the studies were performed in accordance with the Declaration of Helsinki. The purity of plasma cells (80%) was confirmed by monitoring the cell-surface expression of CD38 and CD138. Mononuclear cells were obtained from peripheral blood donated by 3 healthy volunteers who provided informed consent. U266, ARH-77, RPMI8226 (a human multiple myeloma) and MPC-11 (a mouse myeloma) cell lines were purchased from ATCC (Manassas, VA) between 2006 and 2007. MM patient cells and all the cell lines were maintained in RPMI1640 containing 10% fetal bovine serum (FBS) in a state of logarithmic growth at 37°C in humidified air with 5% CO2. To assess in vitro experiment of EGCG, cells were plated in 24-well plates at $1 \times 10^5$ cells/mL and were treated.
with the indicated concentrations of EGCG for the indicated time period in RPMI1640 supplemented with 1% FBS, 200 U/mL catalase and 5 U/mL superoxide dismutase (SOD) (Sigma). All cell lines used in the study were obtained.

**Cell surface ceramide accumulation**

After treatment with EGCG for 3 h, cells were fixed with 2% paraformaldehyde. Cells were washed with PBS and blocked for 1 h in 1% FBS-PBS. Cells were incubated with anti-ceramide antibody (1 mg/mL) (Alexis, Lausen, Switzerland) at 4°C for overnight, followed by incubation with secondary antibody (Alexa Fluor 488) for 30 min. Fluorescent images of cell surface ceramide was analyzed using a fluorescence microscope (Keyence, Tokyo, Japan; Photoshop Software, Adobe Systems, San Jose, CA). ($n = 10$ per group).

**LC-ESI-MS/MS analysis of ceramides**

U266 cells were plated at $5 \times 10^5$ cells/sample and were treated with/without 20 μM of EGCG for 2 h with 5 μM CAY10466 (Cayman Chemical, Michigan, USA). Cells were washed and transferred. Then 25 pmol of each component of Ceamide/Sphingoid Internal Standard Mixture II provided by Avanti Polar Lipids was added as internal standard. After extracting lipids, 24 samples were redissolved with 20% mobile phase B in A solution (described below). A binary solvent gradient with a flow rate of 0.3 mL/min was uses to separate sphingolipids by normal-phase chromatography using an InertSustain NH2 (GL Sciences, Tokyo, Japan). The chromatography was performed at 40°C and the gradient was started a 20% B (methanol/water/formic acid, 89/9/1, v/v/v, with 20 mM ammonium formate) in A (acetonitrile/methanol/formic acid, 97/2/1, v/v/v, with 5 mM ammonium formate) and reached 100% B in 4 min and maintained 100% B for 2 min. Finally, the gradient was returned to the starting conditions and the column was equilibrated for 5 min before the next run. Ceramide levels were determined by liquid chromatography-positive electrospray ionization-tandem
mass spectrometry (LC-ESI-MS/MS) using a triple quadrupole mass spectrometer LCMS-8040 (Shimadzu Corporation, Kyoto, Japan). The detection was performed using multiple reaction monitoring (MRM) mode based on the specific ion transitions for ceramide molecular species as follows: m/z 482.5>264.2, 12:0-Cer; m/z 538.5>264.2, 16:0-Cer; m/z 566.6>264.2, 18:0-Cer; m/z 594.6>264.2, 20:0-Cer; m/z 622.6>264.2, 22:0-Cer; m/z 650.6>264.2, 24:0-Cer; m/z 648.6>264.2, 24:1-Cer. This analytical method was constructed according to previously reported papers (24, 25). (n = 4 per group).

**Western blotting**

Immunoblot analysis was performed as previously described (26).

**Lipid raft clustering assay**

Cells were labeled with 750 nM of DiIC16 labeling solution, then stimulated for varying times with EGCG. After treatment, cells were extracted with 0.5% Triton X-100 on ice for 30 minutes, and then fixed with 2% paraformaldehyde. Fluorescent images of lipid raft staining were analyzed using a fluorescence microscope (Keyence, Tokyo, Japan; Photoshop Software, Adobe Systems, San Jose, CA). (n = 10 per group).

**In vitro cell proliferation and apoptosis assay**

The number of cells was determined by trypan blue exclusion. Apoptotic MM cells were detected using Annexin V-Alexa Fluor 488 (Life Technologies Corporation, Carlsbad, CA, USA). Cells were mixed with Annexin V-Alexa Fluor 488 and media binding reagent, and a portion of the cell suspension was placed onto a glass slide and immediately observed under a fluorescence microscope, BZ-8100 (Keyence, Tokyo, Japan).

For flow cytometry analysis, the cells were double stained with Annexin V-Alexa Fluor 488 and PI. The percentages of Annexin-V⁺ cells were calculated by combining Annexin V⁺/PI⁻ (early Annexin V positive) and Annexin V⁺/PI⁺ (late Annexin V positive), followed by
analysis using a FACSCalibur™ (Becton Dickinson and Company, Franklin Lakes, NJ, USA). 1 × 10^4 cells were plated into 96-well plates and cultured in 1% FBS-RPMI containing the indicated concentrations of compounds in triplicate.

**RTK activity assay**

Cells were pre-cultured in serum-free medium for 24 hours before being treated with the indicated compounds for 24 hours. After treatment, cells were stimulated with 10% FBS-RPMI for 30 minutes and analyzed for phospho-RTKs expression levels using a phosho-RTK array kit (R&D Systems, Minneapolis, MN).

**RNA interference by short hairpin RNA (shRNA)**

Lentiviral pLKO.1 vectors expressing non-targeting control shRNA or shRNAs targeting ASM (TRCN0000230097) and SphK1 (TRCN0000344943) were purchased from Sigma-Aldrich (St Louis, MO). Lentivirus production, transduction and selection were performed according to the manufacturer’s instructions.

**Animals**

BALB/c mice (Kyudo, Saga, Japan) were kept on a 12-hour light/12-hour dark cycle (light on at 8 a.m.) in an air-conditioned room at 20°C and 60% humidity under specific pathogen-free conditions.

**MM xenograft murine model**

Five-week-old female BALB/c mice were inoculated subcutaneously in the interscapular area with 5 × 10^6 MPC-11 cells in 100 μL RPMI 1640 medium. Following the appearance of palpable tumors, mice were divided randomly into groups with an even distribution of tumor sizes (10 mice per group) and injected intraperitoneally daily with saline alone or EGCG (20 mg/kg) or safingol (5 mg/kg) every 2 days. Tumor growth was measured with callipers. Tumor volume was calculated as volume = length × width^2/2. Statistical analysis of survival curves
was performed using log-rank analysis of Kaplan–Meier curves. This experiment was performed in accordance with law #105 and notification #6 of the Japanese government for the welfare of experimental animals. All procedures were approved by the Animal Care and Use Committee of Kyushu University and performed in strict accordance with institutional guidelines for handling laboratory animals.

**Statistical analysis**

Values for the in vitro studies represent the mean ± SD of at least 3 experiments. The significance of difference between the experimental variables was determined by Tukey’s test. Statistical analyses were performed using KyPlot software.
Results

Activated ASM induces lipid raft disruption

We used an ASM assay to identify a dose-dependent increase in ASM activity following treatment of MM U266 cells with low concentrations of EGCG (Fig. 1A). Additionally, microscopic (Fig. 1B) and LC-MS/MS (Fig. 1C) analyses revealed a dose-dependent increase in cell surface ceramide levels in U266 cells following EGCG treatment. Displacement of cholesterol from the lipid raft on the plasma membrane occurs after generation of ceramide by ASM (17), and EGCG has been shown to induce disruption of cholesterol-rich lipid rafts in colon cancer cells (27). Therefore, we next investigated the involvement of ASM in EGCG-induced disruption of lipid raft domains by staining with the lipid-mimetic dialkyl-indocarbocyanine (DilC16) and using a cold Triton X-100 solubility assay (Fig. 1D and E). Exposure of myeloma U266 cells to C16-ceramide or EGCG (> 10 μM) caused a marked reduction in Triton X-100 resistance of the plasma membrane, indicating that EGCG-induced ceramide generation caused lipid raft disruption.

EGCG induces RTK inhibition via ASM activation

Previous studies have concluded that a cholesterol-rich lipid raft can function as a platform and is associated with RTK activation (18). We used a phospho-RTK array kit to determine the effect of EGCG on RTK activation. Treatment with 10 μM EGCG inhibited fetal bovine serum (FBS)-induced phosphorylation of various RTKs, including epidermal growth factor receptor (EGFR), v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) (ErbB2), v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian) (ErbB3), IGF-1R, c-mer proto-oncogene tyrosine kinase (Mer), hepatocyte growth factor (HGF)-R, macrophage-stimulating protein (MSP) R, fms-related tyrosine kinase
3 (Flt-3), and macrophage colony-stimulating factor (M-CSF) R (Fig. 2A, Supplementary Fig. S1). However, EGCG had no influence on the phosphorylation level of most of the RTKs in ASM knockdown U266 cells (Fig. 2B and C). Moreover, pre-treatment with anti-67LR antibodies blocked EGCG-induced inhibition of IGF-1R phosphorylation, suggesting that 67LR/ASM signaling mediates EGCG-induced inactivation of IGF-1R (Fig. 2D).

Next, we performed cold Triton X-100 solubility assays and Western blot analysis on ASM knockdown U266 cells to examine the effect of ASM on lipid raft localization and RTK activity (Fig. 2E–G). Transfection of U266 cells with an shRNA expression vector to reduce ASM expression increased cholesterol-rich lipid raft clustering and phosphorylation of IGF-1R and EGFR, and promoted cell growth. Additionally, safingol potentiated EGCG-induced disruption of cholesterol-rich lipid rafts but did not have an effect on the clustering of ceramide-rich lipid rafts (Supplementary Fig. S2). Collectively, these results suggest that the 67LR/ASM pathway is necessary for EGCG-induced disruption of the lipid raft and inhibition of RTK phosphorylation in U266 cells.

Abnormal over-expression of SphK1 protects cells from EGCG-induced RTK inhibition

Our findings revealed that ASM-generated ceramide contributes to EGCG-induced anti-myeloma activity, suggesting that targeting negative regulators of ceramide could enhance sensitivity to EGCG. EGCG induced ASM activation at low concentrations (1 μM), but did not stimulate ceramide accumulation or disruption of lipid raft formation unless cells were treated with more than 10 μM EGCG. We hypothesized that SphK1 may protect cancer cells from EGCG-induced cell death by down-regulating ceramide levels and up-regulating S1P levels in MM cells (Fig. 3A). We found that SphK1 levels were markedly increased in MM cells isolated from patients, and all human MM cell lines, compared with normal PBMCs from
healthy donors (Fig. 3B). To determine the impact of SphK1 on the EGCG-induced disruption of lipid rafts, cells were treated with EGCG and safingol, an SphK1 inhibitor. We observed significant disruption of the lipid raft and accumulation of ceramide following combination treatment of U266 cells with both EGCG and safingol (Fig. 3C and Supplementary Fig. S3A–B). Additionally, FBS-induced RTK phosphorylation—including that of IGF-1R—was suppressed following treatment of U266 cells with the EGCG/safingol combination (Fig. 3D and E).

SphK1 protects cells from 67LR/ASM-dependent apoptotic cell death induced by EGCG

To determine the impact of SphK1 on the anti-MM activity of EGCG, cells were treated with EGCG and safingol. Safingol treatment potently increased EGCG-induced cell death in MM cells isolated from patient samples and all MM cell lines, while having no observable harmful effect on normal PBMCs (Fig. 4A). This EGCG/safingol-induced specific cell death was attributed to apoptosis (Fig. 4B and C). Treatment with EGCG and safingol in combination resulted in greater inhibition of the growth of U266 cells, with an IC50 of 5.4 μM compared with 28.3 μM for EGCG alone (Supplemental Fig. S4A–C). Isobologram analyses showed that the growth-inhibitory effect of combined treatment with EGCG and safingol on the growth of U266 cells was synergistic (Supplementary Fig. S4D).

SphK2 is another isoform of SphK, therefore, we examined the effects of SphK2 on EGCG-induced cell death. Silencing the expression of SphK2 did not affect the EGCG-induced cell death in U266 myeloma cells (Supplementary Fig. S5A and B). Furthermore, safingol also has an inhibition activity on PKC. Thus, the effect of PKC on EGCG-induced cell death was confirmed by using a potent inhibitor of PKC Ro-318820. Ro-318820 had no enhancement effect on EGCG-induced cell death, either (Supplementary
Fig. S6). However, inhibition of SphK1 expression by gene silencing markedly potentiated the anti-MM effect of EGCG in U266 cells (Fig. 4D and E). Moreover, U266 cells were protected from EGCG/safingol-induced anti-MM activity when ASM protein expression was silenced (Fig. 4F) and when cells were pre-treated with anti-67LR antibodies (Fig. 4G). This suggests that the 67LR/ASM pathway is central to cell death induced by combined EGCG/safingol treatment. These results demonstrate that targeting over-expressed 67LR and SphK1 in MM cells may be a useful approach for cancer-specific killing.

**Combination of EGCG with safingol markedly activates DAPK1 in MM cells**

A previous study has reported that ceramide activates death-associated protein kinase 1 (DAPK1), a key mediator of apoptosis (28). Therefore, we treated U266 cells with or without EGCG and safingol for 96 h to identify the effects of combination EGCG/safingol treatment on DAPK1 activity. Treatment with combination EGCG/safingol reduced p-(Ser308)-DAPK1 levels markedly, leading to increased phosphorylation of the DAPK1 substrate myosin regulatory light chain (MRLC), which induces blebbing in apoptotic cells (Fig. 5A and B). Furthermore, DAPK1 was abnormally elevated in U266 cells compared with normal PBMCs. Treatment of U266 cells with combination EGCG/safingol for 24 h did not have any effect on p-DAPK1 when cells were pre-treated with anti-67LR antibodies or ASM-targeting shRNA (Fig. 5C and D), suggesting that the 67LR/ASM signaling plays a critical role in EGCG/safingol-induced activation of DAPK1.

**Combination EGCG/safingol treatment markedly suppresses tumor growth in vivo**

We evaluated the in vivo activity of combination EGCG/safingol on the growth of MPC-11 cell-derived subcutaneous tumors in female BALB/c mice. Combination EGCG/safingol
treatment did not affect body weight (Supplementary Fig. S7A) or serum ALT/AST activity (Supplementary Fig. S7B). Treatment with EGCG/safingol markedly suppressed tumor growth in mice (Fig. 6A and B). Moreover, log-rank analysis of Kaplan–Meier survival curves revealed a significant increase in the survival rates of mice treated with combination EGCG/safingol compared with mice exposed to EGCG or safingol alone (Fig. 6C). Finally, tumors from mice treated with combination EGCG/safingol had reduced levels of p-DAPK1 and p-IGF-1R (Fig. 6D). These results suggest that co-treatment with safingol increases EGCG-induced anti-tumor activity in mice.

**Discussion**

The proliferation and survival of MM cells has been linked to the activation of several RTKs (including the ErbB family, HGF-R, platelet-derived growth factor receptor [PDGFR] and IGF-1R), and pathways such as phosphatidylinositol-3 kinase (PI-3K)/Akt, Janus kinase (JAK)/signal transducer and activator of transduction 3 (STAT3), mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK), and nuclear factor kappa-B (NF-κB) (29-32). Activation of these pathways is dependent on several growth factors, including interleukin 6, IGF-1, HGF, heparin-binding EGF-like growth factor, and fibroblast growth factor (33-35) IGF-1 decreases drug sensitivity of MM cells and up-regulates a series of anti-apoptotic proteins, including A1/Bfl-1, X chromosome-linked inhibitor of apoptosis (XIAP), and Bcl-2 (36-38). Therefore, modulation of these signaling pathways and/or the signals that initiate them is a potential strategy for cancer therapy.

I-κB kinase (IKK) inhibitors promote MM cell apoptosis, and inhibition of IGF-1 signaling enhances this effect (39). Therefore, inhibiting IGF-1 signaling could enhance the utility of IKK inhibitors for MM treatment. We have demonstrated that ASM-generated ceramide...
negatively regulates lipid raft clustering, leading to suppression of RTKs including IGF-1R. Therefore, promoting ASM-generated ceramide production could inhibit IGF-1R activation and enhance the effectiveness of IKK inhibitors in MM. Moreover, elevated levels of Mer promote proliferation and survival in acute leukemia (acute lymphoblastic leukemia [ALL], AML), breast cancer, astrocytoma, lung cancer, and melanoma (40). Mer silencing increased the sensitivity of ALL cells to a cytotoxic agent in vitro and delayed disease onset in vivo (41). However, little is known about Mer expression in MM cells. We detected aberrant activation of Mer and IGF-1R in U266 cells. Because activation of ASM can suppress these receptors, targeting ASM represents a rational approach to MM therapy.

IGF-1R signaling is impaired by disrupted lipid raft clustering (42). Lipid rafts are plasma membrane micro-domains, comprising cholesterol and sphingolipids in ordered domains that control signal transduction, cellular contacts, pathogen recognition, and internalization processes (43). Chemotherapeutic drug-induced ceramide-rich lipid raft clustering triggers activation of death receptors and apoptotic cell death (44). We have discovered that EGCG can disrupt lipid raft formation and suppress IGF-1R activation by inducing ceramide accumulation through ASM activation.

EGCG-induced anti-myeloma activities mediated by 67LR are highly specific. However, the concentration of EGCG required to induce sufficient ceramide-rich lipid raft clustering exceeds 10 μM, limiting its therapeutic potential. SphK1 is abnormally elevated in many human cancers, including breast, lung, prostate, and colon cancer (20). We hypothesized that SphK1 may protect MM cells from EGCG-induced cell death by down-regulating ceramide levels and up-regulating S1P levels. We found that SphK1 was markedly elevated in MM cells from both human patients and in MM cell lines. We also identified that the SphK1 inhibitor safingol potentiated EGCG-induced lipid raft disruption and IGF-1R inhibition, leading to
markedly suppressed tumor growth in vivo. These results suggest that aberrant expression of SphK1 contributes to EGCG resistance in MM cells.

Hepatotoxicity is an adverse effect of high-dose EGCG (45), and, elevation of the transaminases ALT and AST has been observed in clinical trials (9). Therefore, the our findings hold great clinical value because safingol first entered clinical trials as an anti-cancer agent and no adverse toxicity was seen for doses up to 20 mg/kg (23,46). Importantly, EGCG and safingol in combination did not increase the serum levels of ALT or AST (Supplementary Fig. S4B). Therefore, combination therapy with safingol may enhance the anti-cancer effects of EGCG.

Interestingly, safingol potentiated EGCG-induced disruption of cholesterol-rich lipid rafts but had no effect on the clustering of ceramide-rich lipid rafts (Supplementary Fig. S2). Recent reports have suggested that ceramide production causes a significant displacement of cholesterol from lipid raft membranes (47,48). Therefore, safingol-induced suppression of ceramide degradation may trigger the displacement of cholesterol from lipid raft domains thereby disrupting cholesterol-rich lipid rafts.

DAPK1 is necessary for ceramide-induced cell death in various cell types, and activation of DAPK1 requires dephosphorylation of its Ser308 residue (49). Consistently, we demonstrated that EGCG/safingol in combination caused dephosphorylation of DAPK1 at Ser308 in MM cells with no having an effect on normal PBMCs. Surprisingly, we found that DAPK1 is abnormally elevated in MM cells relative to normal PBMCs. This suggests that activation of DAPK1 could specifically target myeloma cells. Although the mechanism underlying the aberrant expression of DAPK1 in MM is unclear, several reports have suggested that DAPK1 plays a role in survival pathways (in addition to its apoptotic role), which are regulated by domains other than Ser308 (49). Therefore, over-expression of DAPK1
may be involved in the progression of MM, and additional studies are required to determine why DAPK1 is abnormally elevated in MM cells.

We report that EGCG-induced ASM activation triggers RTK inhibition and DAPK1 activation in MM cells. Importantly, these effects are mediated by over-expressed 67LR in cancer cells. Moreover, these effects are impaired by aberrant expression of SphK1 in MM cells. Inhibition of SphK1 activity by treatment with safingol dramatically potentiates EGCG-induced apoptotic activity both in vitro and in vivo. Our results suggest that a new strategy of combining an ASM activator with an SphK1 inhibitor could target cancer cells without indiscriminately affecting normal cells, resulting in less toxicity and better tolerability in patients with myeloma.

Acknowledgments:

We would like to thank Dr. Makoto Ito, Dr. Nozomu Okino, Dr. Daichi Yukihira (Kyushu University), Dr. Toshiro Okazaki (Kanazawa Medical University) for technical assistance.
References


**Figure legends**

**Figure 1.** Activated ASM induces lipid raft disruption. A, ASM activity following treatment with EGCG. B, Cell surface ceramide levels after treatment with EGCG for 3 h. C, LC-MS/MS analysis of ceramide levels after treatment with 20 μM EGCG for 3 h. D and E, U266 cells were stained with DilC16 and then exposed to EGCG (D) or C16-ceramide (E) for 3 h. Fluorescence images of lipid raft staining were analyzed using a fluorescence microscope.

**Figure 2.** EGCG induces RTK inhibition via ASM activation. A, Effect of EGCG on the activities of multiple RTKs. B, shRNA-mediated knock down of ASM in U266 cells. C, Effect of silencing ASM on EGCG-induced inhibition of RTKs in U266 cells. D, U266 cells were pre-treated with either anti-67LR antibodies or control antibodies before stimulation with EGCG (10 μM) for 24 h, and IGF-1R phosphorylation levels were detected by Western blot analysis. E, Effect of silencing ASM on lipid raft clustering in U266 cells. Fluorescence images with lipid raft staining were analyzed using a fluorescence microscope in ASM-knocked down U266 cells. F, Cells, pre-cultured in serum-free medium for 24 h, were stimulated with 10% FBS-RPMI for 30 min and analyzed for phosho-IGF-1R and phosho-EGFR expression levels by Western blot analysis in ASM-knocked down U266 cells. G, Effect of silencing ASM on cell proliferation in U266 cells. Error bars, SD. n = 3 per group. *P < 0.05, **P < 0.01, *** P < 0.001.

**Figure 3.** Abnormal over-expression of SphK1 protects cells from EGCG-induced inhibition of RTKs. A, Schematic of ceramide generation mediated by 67LR/ASM signaling and ceramide metabolism. B, 67LR and SphK1 expression levels in patient MM cell lines and normal PBMCs. C, Lipid raft clustering in U266 cells by treated with 5 μM EGCG/1 μM
safingol. D and E, Effect of 5 μM EGCG/1 μM safingol on the activities of multiple RTKs (D) and IGF-1R phosphorylation (E).

**Figure 4.** SphK1 protects cells from 67LR/ASM-dependent apoptotic cell death induced by EGCG. A–C, Cells treated with 5 μM EGCG/1 μM safingol for 96 h were evaluated. Cell viability was evaluated using the trypan blue exclusion method (A). Apoptotic cells were detected by fluorescence microscopy using Annexin V-Alexa Fluor 488 (B). Apoptotic cells were double-stained with Annexin V-Alexa Fluor 488 and PI (C). D and E, Effect of silencing SphK1 on EGCG-induced cell death in U266 cells. SphK1 was knocked down by SphK1-specific shRNA in U266 cells (D), and the rate of cell lethality assessed using the trypan blue exclusion method (E). F, After treatment with 5 μM EGCG and/or 1 μM Safingol for 96 hours in SphK1 knock down U266 cells, the rate of cell lethality was assessed using the trypan blue exclusion method. G, U266 cells were pre-treated with either anti-67LR antibodies or control antibodies for 1 h before stimulation with EGCG (5 μM) and/or safingol (1 μM) for 96 h, and apoptotic cells were detected using the trypan blue exclusion method. Error bars, SD. n = 3 per group. **P < 0.01, *** or ###P < 0.001.

**Figure 5.** A combination of EGCG with an SphK1 inhibitor activates DAPK1 in MM cells. A, Phosphorylation of DAPK1 and MRLC in U266 cells and normal PBMCs after treatment with 5 μM EGCG/1 μM safingol for 96 h. B, DAPK1 activity in cells treated with 5 μM EGCG/1 μM safingol. C, DAPK1 activity in cells pre-treated with anti-67LR/control antibodies and then treated with EGCG/safingol. D, DAPK1 activity in ASM-knockdown U266 cells after treatment with 5 μM EGCG/1 μM safingol. Error bars, SD. n = 3 per group. * or #P < 0.05, **P < 0.01, ***P < 0.001.
**Figure 6.** Combination EGCG/safingol markedly suppresses tumor growth *in vivo*. A-D, MPC-11 cells were injected subcutaneously into female BALB/c mice, and following the appearance of palpable tumors, the mice were given intraperitoneal injections of EGCG (20 mg/kg) and/or safingol (5 mg/kg). The effect of EGCG alone, safingol alone, or EGCG/safingol combination on flat tumor size (A), tumor growth (B), survival rate (C), and IGF-1R and DAPK1 activity in tumor cells (D) were evaluated. Statistical analysis of survival curves was performed using log-rank analysis of the Kaplan-Meier curves. Error bars, SEM. \( n = 8 \) per group.
Figure 1
**Figure 2**

A

Phospho-RTK (EGCG/Cont, %)

EGFR  | ErbB2 | ErbB3 | FGFR1 | FGFR2a | FGFR3 | IGF-1R | Mer | HGF R | PDGF Ra | PDGF Rb | Flt-3 | M-CSF R

Cont.  | EGCG 5 μM  | EGCG 10 μM

B

shRNA

Scr ASM

β-Actin

C

Phospho-RTK (EGCG/Cont, %)

EGFR  | ErbB2 | ErbB3 | FGFR1 | FGFR2a | FGFR3 | IGF-1R | Mer | HGF R | PDGF Ra | PDGF Rb | Flt-3 | M-CSF R

Scr-shRNA  | ASM-shRNA

D

Cont. Ab Anti-67LR

FBS  | EGCG -  | EGCG +  | EGCG++|

pIGF-1R<sup>Y1131</sup>

IGF-1R

E

DI<sub>16</sub> C16 (%)

Scr-shRNA  | ASM-shRNA

DIB<sub>16</sub> C16 (E)

Scr-shRNA  | ASM-shRNA

F

Phosphorylation (fold change)

Scr shRNA  | ASM shRNA

IGF-1R  | pEGFR<sup>Y1173</sup>

EGFR  | ASM  | β-Actin

G

Cell growth (fold change relative to 0 h)

Scr shRNA  | ASM shRNA

EGCG treatment  | 24 h  | 48 h
**Figure 4**

A. **Cell lethality (%)**

<table>
<thead>
<tr>
<th></th>
<th>Normal PBMCs</th>
<th>Patient 1</th>
<th>Patient 3</th>
<th>U266</th>
<th>RPMI8226</th>
<th>ARH-77</th>
</tr>
</thead>
<tbody>
<tr>
<td>EGCG (µM)</td>
<td>DMSO Safingol</td>
<td>DMSO Safingol</td>
<td>DMSO Safingol</td>
<td>DMSO</td>
<td>DMSO Safingol</td>
<td>DMSO Safingol</td>
</tr>
<tr>
<td>0</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>1</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>5</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

B. **Phase contrast**

<table>
<thead>
<tr>
<th></th>
<th>Normal PBMCs</th>
<th>U266</th>
</tr>
</thead>
<tbody>
<tr>
<td>EGCG</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Safingol</td>
<td>-</td>
<td>+</td>
</tr>
</tbody>
</table>

C. **Annexin V**

<table>
<thead>
<tr>
<th></th>
<th>Cont. EGCG</th>
</tr>
</thead>
<tbody>
<tr>
<td>PE</td>
<td>+</td>
</tr>
<tr>
<td>PI</td>
<td>+</td>
</tr>
</tbody>
</table>

D. **SphK1/β-Actin (%)**

<table>
<thead>
<tr>
<th></th>
<th>Scr</th>
<th>SphK1-shRNA</th>
</tr>
</thead>
<tbody>
<tr>
<td>SphK1</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>β-Actin</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

E. **Cell lethality (%)**

<table>
<thead>
<tr>
<th></th>
<th>Scr-shRNA</th>
<th>SphK1-shRNA</th>
</tr>
</thead>
<tbody>
<tr>
<td>EGCG (µM)</td>
<td>0 1 5</td>
<td>0 1 5</td>
</tr>
</tbody>
</table>

F. **Cell lethality (%)**

<table>
<thead>
<tr>
<th></th>
<th>Cont. EGCG</th>
</tr>
</thead>
<tbody>
<tr>
<td>SAFINGOL</td>
<td>+</td>
</tr>
<tr>
<td>DMSO</td>
<td>-</td>
</tr>
</tbody>
</table>

G. **Cell lethality (%)**

<table>
<thead>
<tr>
<th></th>
<th>Cont. Ab</th>
<th>Anti-67LR</th>
</tr>
</thead>
</table>

---

**Note:**

Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on August 11, 2015; DOI: 10.1158/1535-7163.MCT-15-0185
Figure 5

A

<table>
<thead>
<tr>
<th>PBMCs</th>
<th>U266</th>
</tr>
</thead>
<tbody>
<tr>
<td>EGCG</td>
<td>-</td>
</tr>
<tr>
<td>Safingol</td>
<td>-</td>
</tr>
<tr>
<td>pDAPK1^{S308}</td>
<td>-</td>
</tr>
<tr>
<td>DAPK1</td>
<td>-</td>
</tr>
<tr>
<td>pMRLC^{T18/S19}</td>
<td>-</td>
</tr>
<tr>
<td>67LR</td>
<td>-</td>
</tr>
<tr>
<td>β-Actin</td>
<td>-</td>
</tr>
</tbody>
</table>

B

<table>
<thead>
<tr>
<th>EGCG treatment (h)</th>
</tr>
</thead>
<tbody>
<tr>
<td>24</td>
</tr>
<tr>
<td>48</td>
</tr>
<tr>
<td>72</td>
</tr>
<tr>
<td>96</td>
</tr>
</tbody>
</table>

| EGCG  | -    | +    |
| Safingol | -    | -    |
| pDAPK1^{S308} | -    | +    |
| DAPK1  | -    | -    |

C

<table>
<thead>
<tr>
<th>Cont. Ab</th>
<th>Anti-67LR</th>
</tr>
</thead>
<tbody>
<tr>
<td>EGCG</td>
<td>-</td>
</tr>
<tr>
<td>Safingol</td>
<td>+</td>
</tr>
<tr>
<td>pDAPK1^{S308}</td>
<td>-</td>
</tr>
<tr>
<td>DAPK1</td>
<td>-</td>
</tr>
</tbody>
</table>

D

<table>
<thead>
<tr>
<th>Scr -shRNA</th>
<th>ASM -shRNA</th>
</tr>
</thead>
<tbody>
<tr>
<td>EGCG</td>
<td>-</td>
</tr>
<tr>
<td>Safingol</td>
<td>-</td>
</tr>
<tr>
<td>pDAPK1^{S308}</td>
<td>-</td>
</tr>
<tr>
<td>DAPK1</td>
<td>-</td>
</tr>
</tbody>
</table>
Figure 6
Molecular Cancer Therapeutics

Sphingosine kinase-1 protects multiple myeloma from apoptosis driven by cancer specific inhibition of RTKs

Shuntaro Tsukamoto, Yuhui Huang, Motofumi Kumazoe, et al.

Mol Cancer Ther Published OnlineFirst August 11, 2015.

Updated version  
Access the most recent version of this article at:
doi:10.1158/1535-7163.MCT-15-0185

Supplementary Material  
Access the most recent supplemental material at:
http://mct.aacrjournals.org/content/suppl/2015/08/11/1535-7163.MCT-15-0185.DC1

Author Manuscript  
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts  
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.